Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing beta-galactosylation azo ene glycol and preparation method thereof

A technology for the alkylation of azodiol and galactose, which is applied in the preparation of sugar derivatives, esterified saccharides, chemical instruments and methods, etc., can solve the problems of accelerated degradation, environmental temperature and humidity sensitivity, and organs that do not reach the drug Dosage and other issues, to achieve the effect of prolonging the release time and good tissue specificity

Active Publication Date: 2015-06-17
BEIJING UNIV OF CHEM TECH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, β-galactosylated azocenediol is sensitive to ambient temperature and humidity, and can only be stored at 4 °C for about 10 days. + also accelerates its degradation
If the form of a single drug is used, β-galactosylated azocenediol is easy to release NO in advance when it is stored in the external environment or transported in the body, which affects all organs and sometimes produces serious side effects and complications. In NO-deficient organs, effective drug doses are not achieved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing beta-galactosylation azo ene glycol and preparation method thereof
  • Pharmaceutical composition containing beta-galactosylation azo ene glycol and preparation method thereof
  • Pharmaceutical composition containing beta-galactosylation azo ene glycol and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Combination medicine components: 7g β-galactosylated azoene diol, 5g Xenopuscin, 70g sodium montmorillonite, 18g monostearoyl polyglyceride with a degree of polymerization of 6-14.

[0030] Combination medicine preparation:

[0031] 1) Dissolve 8g of Xenopus in 20ml of ethanol aqueous solution, the volume ratio of ethanol to water is 1:4, then add 70g of montmorillonite, stir, make Xenopuscin fully adsorbed in the montmorillonite, filter, Take the montmorillonite, evaporate the alcohol, and put it in an oven for drying;

[0032] 2) Dissolve 10g of β-galactosylated azoene glycol in 25ml of ethanol, and then add the smectite obtained in step 1) with luteolin adsorbed and stir to make the NO donor drug fully adsorbed on In the montmorillonite, filter, take the montmorillonite, and evaporate the alcohol;

[0033] 3) Add 18 g of monostearoyl polyglycerol ester to the smectite obtained in step 2) with the adsorbed Xenopus and NO donor drug, and mix well to obtain β-galactosylated az...

Embodiment 2

[0035] Combination medicine components: 12g β-galactosylated azoene glycol, 7g xenopuscin, 60g sodium montmorillonite, 21g polydimethylsiloxane with specific gravity of 0.96-0.97.

[0036] Combination medicine preparation:

[0037] 1) Dissolve 10g of Xenopus in 35ml of ethanol aqueous solution, the volume ratio of ethanol to water is 3:7, then add 60g of montmorillonite, stir to make Xenopusin fully absorbed in the montmorillonite, filter, Take the montmorillonite, evaporate the alcohol, and put it in an oven for drying;

[0038] 2) Dissolve 16g of β-galactosylated azoene diol in 30ml of ethanol, and then add the smectite obtained in step 1) with luteolin adsorbed, and stir to make the NO donor drug fully adsorbed on In the montmorillonite, filter, take the montmorillonite, and evaporate the alcohol;

[0039] 3) Add 21 g of stearoyl polyglycerol ester to the montmorillonite adsorbed in step 2) with Xenopus and NO donor drug, and mix well to obtain β-galactosylated azoene Combination...

Embodiment 3

[0041] Combination medicine components: 30g β-galactosylated azoene glycol, 4g xenopuscin, 50g calcium montmorillonite, 16g ethyl cellulose with a molecular weight of 2000.

[0042] Combination medicine preparation:

[0043] 1) Dissolve 6g of Xenopus in 30ml of ethanol aqueous solution, the volume ratio of ethanol to water is 1:4, then add 50g of calcium montmorillonite, stir to make Xenopuscin fully adsorbed in the montmorillonite, filter , Take the montmorillonite, evaporate the alcohol, and put it in an oven for drying;

[0044] 2) Dissolve 30g of β-galactosylated azoene diol in 80ml of ethanol, and then add the smectite obtained in step 1) to adsorb luteolin, and stir to make the NO donor drug fully adsorbed on In the montmorillonite, filter, take the montmorillonite, and evaporate the alcohol;

[0045] 3) Add 16 g of ethyl cellulose to the montmorillonite that has adsorbed xenopus and NO donor drug obtained in step 2), and mix well to obtain β-galactosylated azoene glycol Of co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
degree of polymerizationaaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of medical pharmaceutical engineering, relates to a pharmaceutical composition containing an NO donor and a preparation method thereof, in particular to a pharmaceutical composition containing beta-galactosylation azo ene glycol and a preparation method thereof. The pharmaceutical composition containing beta-galactosylation azo ene glycol provided by the invention comprises NO donor medicine containing beta-galactosylation azo ene glycol, sperm of xenopus laevis, montmorillonite and moisture-proofing agent; and the preparation method of the pharmaceutical composition comprises the following steps of: dissolving sperm of xenopus laevis in alcoholic solution, adding montmorllonite, fully stirring, filtering the montmorillonite, and drying; dissolving the NO donor medicine containing beta-galactosylation azo ene glycol in alcohol, then adding the montmorllonite, fully stirring, filtering the montmorillonite, volatilizing the alcohol and then adding the moisture-proofing agent, and mixing evenly, thus the pharmaceutical composition containing beta-galactosylation azo ene glycol is obtained. The pharmaceutical composition containing beta-galactosylation azo ene glycol provided by the invention is waterproof and antiacid, release time of the NO donor can be prolonged, and stable and controllable aims are achieved.

Description

Technical field [0001] The invention belongs to the technical field of medical pharmacy engineering, and relates to a combination medicine containing an NO donor and a preparation method thereof, in particular to a combination medicine containing β-galactosylated azoene glycol and a preparation method thereof. Background technique [0002] Nitric oxide (NO) is a gaseous small molecule substance with multiple biological activities. In the body, the NO precursor substance L-arginine reacts with oxygen molecules to produce NO and L-guanine under the catalysis of NO precursor substance L-arginine. NO is commonly found in various vertebrate cells, such as endothelial cells, macrophages, and nerve cells. It is an important regulator of intercellular and intracellular information transmission, and it is also a cytotoxic factor in the host immune response. It has been proven to have a variety of biological activities, including regulation of vasodilation and blood flow, nerve signal tra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/16A61K31/7024C07H13/06C07H1/00A61P31/04A61P31/12A61K33/06
Inventor 陈畅姬金丽邓玲玲张会萍田婕
Owner BEIJING UNIV OF CHEM TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com